|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. 149:778–789. 2021. View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pfeiffer RM, Webb-Vargas Y, Wheeler W and
Gail MH: Proportion of US trends in breast cancer incidence
attributable to long-term changes in risk factor distributions.
Cancer Epidemiol Biomarkers Prev. 27:1214–1222. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Globocan, . Saudi Arabia Fact Sheets.
International Agency for Research on Cancer (IARC); Lyon, France:
https://gco.iarc.fr/today/data/factsheets/populations/682-saudi-arabia-fact-sheets.pdfApril
7–2022
|
|
5
|
Albeshan SM and Alashban YI: Incidence
trends of breast cancer in Saudi Arabia: A Joinpoint regression
analysis (2004–2016). J King Saud Univ Sci. 33:1015782021.
View Article : Google Scholar
|
|
6
|
Jazieh AR, Da'ar OB, Alkaiyat M, Zaatreh
YA, Saad AA, Bustami R, Alrujaib M and Alkattan K: Cancer incidence
trends from 1999 to 2015 and contributions of various cancer types
to the overall burden: Projections to 2030 and extrapolation of
economic burden in Saudi Arabia. Cancer Manag Res. 11:9665–9674.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Albeshan SM, Mackey MG, Hossain SZ,
Alfuraih AA and Brennan PC: Breast cancer epidemiology in gulf
cooperation council countries: A regional and international
comparison. Clin Breast Cancer. 18:e381–e392. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Assidi M, Jafri MA, Abu-Elmagd M, N
Pushparaj P, Saddick S, Messaoudi S, Alkhatabi H, Al-Maghrabi J,
Anfinan N, Sait M, et al: Prognostic value of E-Cadherin and its
tumor suppressor role in Saudi women with advanced epithelial
ovarian cancer. Libyan J Med. 16:19947412021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lumachi F, Luisetto G, MM Basso S, Basso
U, Brunello A and Camozzi V: Endocrine therapy of breast cancer.
Current Med Chem. 18:513–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang CY, Ju DT, Chang CF, Reddy PM and
Velmurugan BK: A review on the effects of current chemotherapy
drugs and natural agents in treating non-small cell lung cancer.
Biomedicine (Taipei). 7:232017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allison KH, Hammond MEH, Dowsett M,
McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR,
Chavez-MacGregor M, Perlmutter J, et al: Estrogen and progesterone
receptor testing in breast cancer: ASCO/CAP guideline update. J
Clin Oncol. 38:1346–1366. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Purdie CA, Quinlan P, Jordan LB, Ashfield
A, Ogston S, Dewar JA and Thompson AM: Progesterone receptor
expression is an independent prognostic variable in early breast
cancer: A population-based study. Br J Cancer. 110:565–572. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Petroni S, Caldarola L, Scamarcio R,
Giotta F, Latorre A, Mangia A and Simone G: FISH testing of HER2
immunohistochemistry 1+ invasive breast cancer with unfavorable
characteristics. Oncol Lett. 12:3115–3122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brown JR, DiGiovanna MP, Killelea B,
Lannin DR and Rimm DL: Quantitative assessment Ki-67 score for
prediction of response to neoadjuvant chemotherapy in breast
cancer. Lab Invest. 94:98–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lampelj M, Arko D, Cas-Sikosek N, Kavalar
R, Ravnik M, Jezersek-Novakovic B, Dobnik S, Dovnik NF and Takac I:
Urokinase plasminogen activator (uPA) and plasminogen activator
inhibitor type-1 (PAI-1) in breast cancer-correlation with
traditional prognostic factors. Radiol Oncol. 49:357–364. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parrales A and Iwakuma T: Targeting
oncogenic mutant p53 for cancer therapy. Front Oncol. 5:2882015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bi H, Li S, Qu X, Wang M, Bai X, Xu Z, Ao
X, Jia Z, Jiang X, Yang Y and Wu H: DEC1 regulates breast cancer
cell proliferation by stabilizing cyclin E protein and delays the
progression of cell cycle S phase. Cell Death Dis. 6:e1891. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Al-Keilani MS, Elstaty RI, Alqudah MA and
Alkhateeb AM: Immunohistochemical expression of substance P in
breast cancer and its association with prognostic parameters and
Ki-67 index. PLoS One. 16:e02526162021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tray N, Weber JS and Adams S: Predictive
biomarkers for checkpoint immunotherapy: Current status and
challenges for clinical application. Cancer Immunol Res.
6:1122–1128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Emens LA, Cruz C, Eder JP, Braiteh F,
Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, et
al: Long-term clinical outcomes and biomarker analyses of
Atezolizumab therapy for patients with metastatic Triple-negative
breast cancer: A phase 1 study. JAMA Oncol. 5:74–82. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Waldman AD, Fritz JM and Lenardo MJ: A
guide to cancer immunotherapy: From T cell basic science to
clinical practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keefe DMK and Bateman EH: Potential
successes and challenges of targeted cancer therapies. J Natl
Cancer Inst Monogr. 2019:lgz0082019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akbulut H, Babahan C, Abgarmi SA, Ocal M
and Besler M: Recent advances in cancer stem cell targeted therapy.
Crit Rev Oncog. 24:1–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tai YT, Dillon M, Song W, Leiba M, Li XF,
Burger P, Lee AI, Podar K, Hideshima T, Rice AG, et al: Anti-CS1
humanized monoclonal antibody HuLuc63 inhibits myeloma cell
adhesion and induces antibody-dependent cellular cytotoxicity in
the bone marrow milieu. Blood. 112:1329–1337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boles KS and Mathew PA: Molecular cloning
of CS1, a novel human natural killer cell receptor belonging to the
CD2 subset of the immunoglobulin superfamily. Immunogenetics.
52:302–307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsi ED, Steinle R, Balasa B, Szmania S,
Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y,
et al: CS1, a potential new therapeutic antibody target for the
treatment of multiple myeloma. Clin Cancer Res. 14:2775–2784. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lonial S, Dimopoulos M, Palumbo A, White
D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV,
Magen H, et al: Elotuzumab therapy for relapsed or refractory
multiple myeloma. N Engl J Med. 373:621–631. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bouchon A, Cella M, Grierson HL, Cohen JI
and Colonna M: Cutting edge: Activation of NK cell-mediated
cytotoxicity by a SAP-independent receptor of the CD2 family. J
Immunol. 167:5517–5521. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kumaresan PR, Lai WC, Chuang SS, Bennett M
and Mathew PA: CS1, a novel member of the CD2 family, is homophilic
and regulates NK cell function. Mol Immunol. 39:1–8. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Zhong MC, Guo H, Davidson D,
Mishel S, Lu Y, Rhee I, Pérez-Quintero LA, Zhang S, Cruz-Munoz ME,
et al: SLAMF7 is critical for phagocytosis of haematopoietic tumour
cells via Mac-1 integrin. Nature. 544:493–497. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pazina T, James AM, MacFarlane AW IV,
Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD and
Campbell KS: The anti-SLAMF7 antibody elotuzumab mediates NK cell
activation through both CD16-dependent and-independent mechanisms.
Oncoimmunology. 6:e13398532017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Simmons DP, Nguyen HN, Gomez-Rivas E,
Jeong Y, Jonsson AH, Chen AF, Lange JK, Dyer GS, Blazar P, Earp BE,
et al: SLAMF7 engagement superactivates macrophages in acute and
chronic inflammation. Sci Immunol. 7:eabf28462022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Campbell KS, Cohen AD and Pazina T:
Mechanisms of NK cell activation and clinical activity of the
therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma. Front
Immunol. 9:25512018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lonial S, Dimopoulos M, Palumbo A, White
D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV,
Magen H, et al: Elotuzumab therapy for relapsed or refractory
multiple myeloma. N Engl J Med. 373:621–631. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JL, Roh SA, Kim CW, Kwon YH, Ha YJ,
Kim SK, Kim SY, Cho DH, Kim YS and Kim JC: Clinical assessment and
identification of immuno-oncology markers concerning the 19-gene
based risk classifier in stage IV colorectal cancer. World J
Gastroenterol. 25:1341–1354. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, Zhou H, Huang W, Wang X, Meng M, Hou
Z, Liao L, Tang W, Xie Y, Wang R, et al: Retrospective analysis of
the efficacy of adjuvant cytokine-induced killer cell immunotherapy
combined with chemotherapy in colorectal cancer patients after
surgery. Clin Transl Immunol. 11:e13682022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roh SA, Kwon YH, Lee JL, Kim SK and Kim
JC: SLAMF7 and TREM1 mediate immunogenic cell death in colorectal
cancer cells: Focus on microsatellite stability. Anticancer Res.
41:5431–5444. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Su R, Jin C, Zhou L, Gao Y, Kuang M, Li L
and Xiang J: Construction of a ceRNA network of hub genes affecting
immune infiltration in ovarian cancer identified by WGCNA. BMC
Cancer. 21:9702021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen H, Wang T, Huang S and Zeng P: New
novel non-MHC genes were identified for cervical cancer with an
integrative analysis approach of transcriptome-wide association
study. J Cancer. 12:840–848. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sun H, Kim E, Ryu J, Lee H, Shin EA, Lee
M, Lee H, Lee HJ, Yoon JH, Song DG, et al: TM4SF5-mediated liver
malignancy involves NK cell exhaustion-like phenotypes. Cell Mol
Life Sci. 79:492021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
O'Connell P, Blake MK, Pepelyayeva Y,
Hyslop S, Godbehere S, Angarita AM, Pereira-Hicks C, Amalfitano A
and Aldhamen YA: Adenoviral delivery of an immunomodulatory protein
to the tumor microenvironment controls tumor growth. Mol Ther
Oncolytics. 24:180–193. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Al-Maghrabi J, Emam E, Gomaa W, Saggaf M,
Buhmeida A, Al-Qahtani M and Al-Ahwal M: c-MET immunostaining in
colorectal carcinoma is associated with local disease recurrence.
BMC Cancer. 15:6762015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nedjadi T, Al-Maghrabi J, Assidi M, Dallol
A, Al-Kattabi H, Chaudhary A, Al-Sayyad A, Al-Ammari A, Abuzenadah
A, Buhmeida A and Al-Qahtani M: Prognostic value of HER2 status in
bladder transitional cell carcinoma revealed by both IHC and BDISH
techniques. BMC Cancer. 16:6532016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Assidi M, Yahya FM, Al-Zahrani MH,
Elkhatib R, Zari A, Elaimi A, Al-Maghrabi J, Dallol A, Buhmeida A
and Abu-Elmagd M: Leptin protein expression and promoter
methylation in ovarian cancer: A strong prognostic value with
theranostic promises. Int J Mol Sci. 22:128722021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Buhmeida A, Dallol A, Merdad A,
Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Chaudhary AG, Abuzenadah AM,
Nedjadi T, Ermiah E, et al: High fibroblast growth factor 19
(FGF19) expression predicts worse prognosis in invasive ductal
carcinoma of breast. Tumour Biol. 35:2817–2824. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Goldman MJ, Craft B, Hastie M, Repečka K,
McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al:
Visualizing and interpreting cancer genomics data via the Xena
platform. Nat Biotechnol. 38:675–678. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cronin KA, Lake AJ, Scott S, Sherman RL,
Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et
al: Annual report to the nation on the status of cancer, part I:
National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiang M, Yang JS, Li K, Liu J, Jing XG and
Tang MQ: Insights into the theranostic value of precision medicine
on advanced radiotherapy to breast cancer. Int J Med Sci.
18:626–638. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Society AC: Cancer facts & figures
2012. Atlanta: American Cancer Society; pp. 9–11. 2012
|
|
51
|
Lai FM, Chen P, Ku HC, Lee MS, Chang SC,
Chang TM and Liou SH: A case-control study of parity, age at first
full-term pregnancy, breast feeding and breast cancer in Taiwanese
women. Proc Natl Sci Counc Repub China B. 20:71–77. 1996.PubMed/NCBI
|
|
52
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Reis-Filho JS and Pusztai L: Gene
expression profiling in breast cancer: Classification,
prognostication, and prediction. Lancet. 378:1812–1823. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Garrido-Castro AC, Lin NU and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Strategies for subtypes-dealing with
the diversity of breast cancer: Highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kim JR, Horton NC, Mathew SO and Mathew
PA: CS1 (SLAMF7) inhibits production of proinflammatory cytokines
by activated monocytes. Inflamm Res. 62:765–772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li X, Zhou H, Huang W, Wang X, Meng M, Hou
Z, Liao L, Tang W, Xie Y, Wang R, et al: Retrospective analysis of
the efficacy of adjuvant cytokine-induced killer cell immunotherapy
combined with chemotherapy in colorectal cancer patients after
surgery. Clin Transl Immunol. 11:e13682022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Thul PJ and Lindskog C: The human protein
atlas: A spatial map of the human proteome. Protein Sci.
27:233–244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Tissue-based map of the human
proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Uhlen M, Zhang C, Lee S, Sjöstedt E,
Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et
al: A pathology atlas of the human cancer transcriptome. Science.
357:eaan25072017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zekri J, Saadeddin A and Alharbi H:
Frequency and clinical characteristics of HER2 over-expressed
breast cancer in Saudi Arabia: A retrospective study. BMC Womens
Health. 21:102021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Weigel MT and Dowsett M: Current and
emerging biomarkers in breast cancer: Prognosis and prediction.
Endocrine-related Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Saggu S, Rehman H, Abbas ZK and Ansari AA:
Recent incidence and descriptive epidemiological survey of breast
cancer in Saudi Arabia. Saudi Med J. 36:1176–1180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Albasri A, Hussainy AS, Sundkji I and
Alhujaily A: Histopathological features of breast cancer in
Al-Madinah region of Saudi Arabia. Saudi Med J. 35:1489–1493.
2014.PubMed/NCBI
|
|
66
|
Howlader N, Noone A, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al:
SEER cancer statistics review, 1975–2016, National Cancer
Institute. Bethesda, MD: https://seer.cancer.gov/csr/1975_2016/based on
November 2018 SEER data submission, posted to the SEER web site.
April. 2019
|
|
67
|
Najjar H and Easson A: Age at diagnosis of
breast cancer in Arab nations. Int J Surg. 8:448–452. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Müller L and Pawelec G: Aging and
immunity-impact of behavioral intervention. Brain Behav Immunity.
39:8–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Valcárcel LV, Amundarain A, Kulis M,
Charalampopoulou S, Melnick A, San Miguel J, Martín-Subero JI,
Planes FJ, Agirre X and Prosper F: Gene expression derived from
alternative promoters improves prognostic stratification in
multiple myeloma. Leukemia. 35:3012–3016. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Malaer JD and Mathew PA: CS1 (SLAMF7,
CD319) is an effective immunotherapeutic target for multiple
myeloma. Am J Cancer Res. 7:1637–1641. 2017.PubMed/NCBI
|
|
71
|
Boudreault JS, Touzeau C and Moreau P: The
role of SLAMF7 in multiple myeloma: Impact on therapy. Expert Rev
Clin Immunol. 13:67–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Pham T, Roth S, Kong J, Guerra G,
Narasimhan V, Pereira L, Desai J, Heriot A and Ramsay R: An update
on immunotherapy for solid tumors: A review. Ann Surg Oncol.
25:3404–3412. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chandrashekar DS, Karthikeyan SK, Korla
PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne
U, et al: UALCAN: An update to the integrated cancer data analysis
platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Detre C, Keszei M, Romero X, Tsokos GC and
Terhorst C: SLAM family receptors and the SLAM-associated protein
(SAP) modulate T cell functions. Semin Immunopathol. 32:157–171.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wu N and Veillette A: SLAM family
receptors in normal immunity and immune pathologies. Curr Opin
Immunol. 38:45–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Claus M, Urlaub D, Fasbender F and Watzl
C: SLAM family receptors in natural killer cells-mediators of
adhesion, activation and inhibition via cis and Trans interactions.
Clin Immunol. 204:37–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
